`
`{not}; of {Brat Compound 3"le steers Frtmary Endpoint in guitipse Sclerosis
`
`Hafisfioom
`
`1/9/06 Bus. Wire 13:30:00
`
`Business Wire
`
`Copyright © 2006 Business Wire
`
`January 9, 2006
`
`l’hase II Stanly of Oral Compound 34343 Meets Primary Endpoint in Multiple Sclerosis
`
`BIOWIREEK CAMBRIDGE. Mass. 8: LUCERNE, Switzerland-{BUSINESS WIRE-Jan. 9t 2006--Biogen Idec
`(NASDAQ: 8118) and Fumapharrn AG today announced that a Phase II study designed to evaluate the efficacy and
`safety of BG-ll, an oral fumarate, in patients with relapsing—remitting multiple sclerosis (MS) met its primary endpoint.
`Treatment with BG-12 led to a statistically significant reduction in the total number of gadolinium—enhancing brain
`lesions as measured by MRI with six months of treatment versus placebo. This Phase II multicenter, double-blind,
`
`placebo-controlled study enrolled approximately 250 patients at sites in 10 countries in Europe.
`
`About Biogen Idec
`
`leader in the
`Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global
`development; manufacturing. and commercialization of novel therapies; Biogen Idec transforms scientific discoveries
`
`into advances in human healthcare. For press releases and additional information about the company, please Visit http:/f
`wwwbiogenidcccom.
`
`About Fumapharm AG
`
`Fumapharm has licensed exclusive worldwide rights to develop and market 80-12 to Biogen Idec; Fumapharm is a
`privately held pharmaceutical company headquartered in Lucerne, Switzerland. For more information. please Visit httpzf/
`wwwfumapharmch.
`
`CONTACT: Biogen Idec MEDIA CONTACT: Amy Brockelman, 617-9l4-6524 Senior Manager, Public Affairs or
`INVESTOR CONTACT: Oscar Velastegui, 61?-679—28l2 Senior Manager. Investor Relations
`KEYWORD: MASSACHUSETTS SWITZERLANX) INTERNATIONAL LATIN AMERICAEUROPE
`INQUS’TRY KEYWORQ: PHARMACEUTICAL MEDICAL BIOTECHNQLOGY PRODUCT
`
`SOLIRifE: Brogan ldec
`
`-- Index References m
`
`Company: BIOGEN IDEC INC
`
`News Subg'cct: {Major Corporations {tMAQE};
`
`industry: {Pharn‘saceuticaés 8: gioteclmologgr {£9313}; Immunology {nines}; Moscuiar 3: Neuromusceiar Sisease
`
`t i M890}; atanafactaring { t stare}; Biopnarrnaceoticaia { l B} l 3}; rteaitneare { i £13003; Allergy 3e ,lmmnsology { 1 2363353;
`
`Sawai (IPR2019-00789), Ex. 1005, p. 001
`
`
`
`@2356 E $13.33? :3? Great {ifimpegflé 3342 Mega ¥3r§mar3¢ gfiéggiai $3“; figufiifie fieigmsig
`
`Nearoiogy (1NE9S); Multiplfi Sciei’osis & Demyeiinaiion {13411388}; 3:21am} Medicine (iiNSs-i}; Healiizcare Practice
`Spaciaifies GEES-$9};
`
`Ragiim: {Americas {iAMQZ}; Nam Amgrizza {155039}; Wegmm Europe {iWEdi}; Latifl Amgrica {iLAié}; Europa
`{iEUSB}; {ESA { §US?3); Genital Eurepe {‘1CE58); Switzaflafid (15%??733
`
`Laaguage: EN
`
`Gather Imiexing: (AG; BiOGEN IDEC; FUMAPHAR’M; FUMAPHARM AG; NASEAQ: BEBE {Am}; Bmekelman;
`03m: Veiaszegai; Phase; Public Affairs}
`
`Keywords: MASSACHUSETTS SWITZERLAND {NTERNATIQNAL LATIN AMERICAEUROPE if};
`{PHARMACEUTICAL MEDICAL BIOTECHNOLOGY PRGDUCT}
`
`Ticker 531113301: NASDAQBIIB
`
`Ward Gaunt: 331
`
`
`
` 333% a? géwgmafi
`
`szsfimm
`
`Sawai (IPR2019-00789), Ex. 1005, p. 002
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
